Amniocentesis in pregnancies at or beyond 24 weeks: An international multicenter study.

Chromosomal microarray analysis exome sequencing fetal anomalies genetic testing late amniocentesis next-generation sequencing panel prenatal diagnosis preterm birth third trimester amniocentesis

Journal

American journal of obstetrics and gynecology
ISSN: 1097-6868
Titre abrégé: Am J Obstet Gynecol
Pays: United States
ID NLM: 0370476

Informations de publication

Date de publication:
22 Jun 2024
Historique:
received: 08 03 2024
revised: 12 06 2024
accepted: 19 06 2024
medline: 25 6 2024
pubmed: 25 6 2024
entrez: 24 6 2024
Statut: aheadofprint

Résumé

Amniocentesis for genetic diagnosis is most commonly done between 15 and 22 weeks of gestation, but can be performed at later gestational ages. The safety and genetic diagnostic accuracy of amniocentesis have been well-established through numerous large-scale, multicenter studies for procedures before 24 weeks, but comprehensive data on late amniocentesis remain sparse. To evaluate the indications, diagnostic yield, safety, and maternal and fetal outcomes associated with amniocentesis performed at or beyond 24 weeks of gestation. We conducted an international, multicenter retrospective cohort study examining pregnant individuals who underwent amniocentesis for prenatal diagnostic testing at gestational ages between 24w0d and 36w6d. The study, spanning from 2011 to 2022, involved nine referral centers. We included singleton or twin pregnancies with documented outcomes, excluding cases where other invasive procedures were performed during pregnancy or if amniocentesis was conducted for obstetric indications. We analyzed indications for late amniocentesis, types of genetic tests performed, their results, and the diagnostic yield, along with pregnancy outcomes and post-procedure complications. Of the 752 pregnant individuals included in our study, late amniocentesis was primarily performed for the prenatal diagnosis of structural anomalies (91.6%), followed by suspected fetal infection (2.3%) and high-risk findings from cell-free DNA screening (1.9%). The median gestational age at the time of the procedure was 28w5d, and 98.3% of pregnant individuals received results of genetic testing before birth or pregnancy termination. The diagnostic yield was 22.9%, and a diagnosis was made 2.4 times more often for fetuses with anomalies in multiple organ systems (36.4%) compared to those with anomalies in a single organ system (15.3%). Additionally, the diagnostic yield varied depending on the specific organ system involved, with the highest yield for musculoskeletal anomalies (36.7%) and hydrops fetalis (36.4%) when a single organ system or entity was affected. The most prevalent genetic diagnoses were aneuploidies (46.8%), followed by copy number variants (26.3%) and monogenic disorders (22.2%). The median gestational age at delivery was 38w3d, with an average of 59 days between the procedure and delivery date. The overall complication rate within two weeks post-procedure was 1.2%. We found no significant difference in the rate of preterm delivery between pregnant individuals undergoing amniocentesis between 24-28 weeks and those between 28-32 weeks, reinforcing the procedure's safety across these gestational periods. Late amniocentesis, at or after 24 weeks gestation, especially for pregnancies complicated by multiple congenital anomalies, has a high diagnostic yield and a low complication rate, underscoring its clinical utility. It provides pregnant individuals and their providers with a comprehensive diagnostic evaluation and results before delivery, enabling informed counseling and optimized perinatal and neonatal care planning.

Sections du résumé

BACKGROUND BACKGROUND
Amniocentesis for genetic diagnosis is most commonly done between 15 and 22 weeks of gestation, but can be performed at later gestational ages. The safety and genetic diagnostic accuracy of amniocentesis have been well-established through numerous large-scale, multicenter studies for procedures before 24 weeks, but comprehensive data on late amniocentesis remain sparse.
OBJECTIVES OBJECTIVE
To evaluate the indications, diagnostic yield, safety, and maternal and fetal outcomes associated with amniocentesis performed at or beyond 24 weeks of gestation.
STUDY DESIGN METHODS
We conducted an international, multicenter retrospective cohort study examining pregnant individuals who underwent amniocentesis for prenatal diagnostic testing at gestational ages between 24w0d and 36w6d. The study, spanning from 2011 to 2022, involved nine referral centers. We included singleton or twin pregnancies with documented outcomes, excluding cases where other invasive procedures were performed during pregnancy or if amniocentesis was conducted for obstetric indications. We analyzed indications for late amniocentesis, types of genetic tests performed, their results, and the diagnostic yield, along with pregnancy outcomes and post-procedure complications.
RESULTS RESULTS
Of the 752 pregnant individuals included in our study, late amniocentesis was primarily performed for the prenatal diagnosis of structural anomalies (91.6%), followed by suspected fetal infection (2.3%) and high-risk findings from cell-free DNA screening (1.9%). The median gestational age at the time of the procedure was 28w5d, and 98.3% of pregnant individuals received results of genetic testing before birth or pregnancy termination. The diagnostic yield was 22.9%, and a diagnosis was made 2.4 times more often for fetuses with anomalies in multiple organ systems (36.4%) compared to those with anomalies in a single organ system (15.3%). Additionally, the diagnostic yield varied depending on the specific organ system involved, with the highest yield for musculoskeletal anomalies (36.7%) and hydrops fetalis (36.4%) when a single organ system or entity was affected. The most prevalent genetic diagnoses were aneuploidies (46.8%), followed by copy number variants (26.3%) and monogenic disorders (22.2%). The median gestational age at delivery was 38w3d, with an average of 59 days between the procedure and delivery date. The overall complication rate within two weeks post-procedure was 1.2%. We found no significant difference in the rate of preterm delivery between pregnant individuals undergoing amniocentesis between 24-28 weeks and those between 28-32 weeks, reinforcing the procedure's safety across these gestational periods.
CONCLUSIONS CONCLUSIONS
Late amniocentesis, at or after 24 weeks gestation, especially for pregnancies complicated by multiple congenital anomalies, has a high diagnostic yield and a low complication rate, underscoring its clinical utility. It provides pregnant individuals and their providers with a comprehensive diagnostic evaluation and results before delivery, enabling informed counseling and optimized perinatal and neonatal care planning.

Identifiants

pubmed: 38914189
pii: S0002-9378(24)00693-8
doi: 10.1016/j.ajog.2024.06.025
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Roni Zemet (R)

Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Tx, USA. Electronic address: roni.zemetlazar@bcm.edu.

Mohamad Ali Maktabi (M)

Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Tx, USA.

Alexandra Tinfow (A)

Department of Obstetrics and Gynecology, Columbia University Irving Medical Center, New York, NY, USA.

Jessica L Giordano (JL)

Department of Obstetrics and Gynecology, Columbia University Irving Medical Center, New York, NY, USA.

Thomas M Heisler (TM)

Department of Obstetrics and Gynecology, Columbia University Irving Medical Center, New York, NY, USA.

Qi Yan (Q)

Department of Obstetrics and Gynecology, Columbia University Irving Medical Center, New York, NY, USA.

Roni Plaschkes (R)

Department of Obstetrics and Gynecology, Sheba Medical Center, Tel-Hashomer, Israel.

Jenny Stokes (J)

Department of Obstetrics and Gynaecology, National Maternity Hospital, Dublin, Ireland.

Jennifer M Walsh (JM)

Department of Obstetrics and Gynaecology, National Maternity Hospital, Dublin, Ireland.

Siobhán Corcoran (S)

Department of Obstetrics and Gynaecology, National Maternity Hospital, Dublin, Ireland.

Erica Schindewolf (E)

The Center for Fetal Diagnosis and Treatment, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.

Kendra Miller (K)

The Center for Fetal Diagnosis and Treatment, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.

Asha N Talati (AN)

Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA.

Kristen A Miller (KA)

Department of Gynecology and Obstetrics, Division of Maternal-Fetal Medicine, Johns Hopkins University School of Medicine Baltimore, MD, USA.

Karin Blakemore (K)

Department of Gynecology and Obstetrics, Division of Maternal-Fetal Medicine, Johns Hopkins University School of Medicine Baltimore, MD, USA.

Kate Swanson (K)

Department of Obstetrics, Gynecology, and Reproductive Sciences, Division of Maternal-Fetal Medicine, University of California, San Francisco, California, USA.

Jana Ramm (J)

Department of Prenatal Diagnosis and Fetal Therapy, Justus-Liebig University, Giessen, Germany.

Ivonne Bedei (I)

Department of Prenatal Diagnosis and Fetal Therapy, Justus-Liebig University, Giessen, Germany.

Teresa N Sparks (TN)

Department of Obstetrics, Gynecology, and Reproductive Sciences, Division of Maternal-Fetal Medicine, University of California, San Francisco, California, USA.

Angie C Jelin (AC)

Department of Gynecology and Obstetrics, Division of Maternal-Fetal Medicine, Johns Hopkins University School of Medicine Baltimore, MD, USA.

Neeta L Vora (NL)

Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA.

Juliana S Gebb (JS)

The Center for Fetal Diagnosis and Treatment, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.

David A Crosby (DA)

Department of Obstetrics and Gynaecology, National Maternity Hospital, Dublin, Ireland.

Michal Berkenstadt (M)

The Danek Gertner Institute of Human Genetics, Sheba Medical Center, Tel-Hashomer, Israel.

Boaz Weisz (B)

Department of Obstetrics and Gynecology, Sheba Medical Center, Tel-Hashomer, Israel.

Ronald J Wapner (RJ)

Department of Obstetrics and Gynecology, Columbia University Irving Medical Center, New York, NY, USA.

Ignatia B VAN DEN Veyver (IB)

Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Tx, USA; Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine and Reproductive and Prenatal Genetics, Baylor College of Medicine and Texas Children's Fetal Center, Houston, Tx. Electronic address: iveyver@bcm.edu.

Classifications MeSH